繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药推荐 >> 考比替尼薄膜片|Cotellic(cobimetinib filmcoated tablets)

考比替尼薄膜片|Cotellic(cobimetinib filmcoated tablets)

2016-02-15 02:58:14  作者:新特药房  来源:互联网  浏览次数:70  文字大小:【】【】【
简介: 2015年11月17日,欧盟委员会批准罗氏Cotellic(cobimetinib)与威罗菲尼合并用于有BRAF V600突变的不可切除或转移性黑色素瘤成年患者治疗。此次,欧盟的批准基于3期coBRIM研究数据,数据显示,在既往未治 ...

2015年11月17日,欧盟委员会批准罗氏Cotellic(cobimetinib)与威罗菲尼合并用于有BRAF V600突变的不可切除或转移性黑色素瘤成年患者治疗。
此次,欧盟的批准基于3期coBRIM研究数据,数据显示,在既往未治疗的BRAF V600突变阳性晚期黑色素瘤患者中,以MEK抑制剂Cotellic与威罗菲尼合并治疗患者其疾病在未进展的情况下平均生存12.3个月,相比之下,那些仅以威罗菲尼治疗的患者平均生存了7.2个月。同时,在coBRIM 研究中,合并用药治疗患者的客观缓解率为70%,威罗菲尼治疗组的客观缓解率为50%。
与威罗菲尼单药治疗相比,Cotellic+威罗菲尼使总生存期得改善
黑色素瘤治疗已取得重大进展,与之前的30年相比,过去5年批准了更多的药物,罗氏首席医疗官兼全球产品发展总监、医学博士Horning称。总之,与威罗菲尼单药治疗相比,Cotellic+威罗菲尼更强大地抑制了癌症的生长。这凸显了合并用药的关键作用,以帮助黑色素瘤患者在疾病未进展的情况下存活得更久。
在今年黑色素瘤研究学会大会上公布的其它数据证明,Cotellic+威罗菲尼的合并用药达到了其次要终点,即与威罗菲尼相比改善了总生存期。罗氏计划向欧洲药品管理局提交这些数据,以寻求扩展这款药物的标签。在美国,该合并用药获批用于BRAF V600E或V600K 突变阳性晚期黑色素瘤患者治疗。2016年,该合并用药有望获得进一步的批准。
Cotellic 20 mg film-coated tablets
1. Name of the medicinal product
Cotellic 20 mg film-coated tablets
2. Qualitative and quantitative composition
Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib.
Excipient with known effect:
Each film-coated tablet contains 36 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet.
White, round film-coated tablets of approximately 6.6 mm diameter, with “COB” debossed on one side.
4. Clinical particulars
4.1 Therapeutic indications
Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).
4.2 Posology and method of administration
Treatment with Cotellic in combination with vemurafenib should only be initiated and supervised by a qualified physician experienced in the use of anticancer medicinal products.
Before starting this treatment, patients must have BRAF V600 mutation-positive melanoma tumour status confirmed by a validated test (see sections 4.4 and 5.1).
Posology
The recommended dose of Cotellic is 60 mg (3 tablets of 20 mg) once daily.
Cotellic is taken on a 28 day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent Cotellic treatment cycle should start after the 7-day treatment break has elapsed.
For information on the posology of vemurafenib, please refer to its SmPC.
Duration of treatment
Treatment with Cotellic should continue until the patient no longer derives benefit or until the development of unacceptable toxicity (see Table 1 below).
Missed doses
If a dose is missed, it can be taken up to 12 hours prior to the next dose to maintain the once-daily regimen.
Vomiting
In case of vomiting after administration of Cotellic, the patient should not take an additional dose on that day and treatment should be continued as prescribed the following day.
General dose modifications
The decision on whether to reduce the dose for either or both treatments should be based on the prescriber's assessment of individual patient safety or tolerability. Dose modification of Cotellic is independent of vemurafenib dose modification.
If doses are omitted for toxicity, these doses should not be replaced. Once the dose has been reduced, it should not be increased at a later time.
Table 1 below gives general Cotellic dose modification guidance.
Table 1 Recommended Cotellic dose modifications

Grade (CTC-AE)*

Recommended Cotellic dose

Grade 1 or Grade 2 (tolerable)

No dose reduction. Maintain Cotellic at a dose of 60 mg once daily (3 tablets)

Grade 2 (intolerable) or Grade 3/4

 

1st Appearance

Interrupt treatment until Grade ≤ 1, restart treatment at 40 mg once daily (2 tablets)

2nd Appearance

Interrupt treatment until Grade ≤ 1, restart treatment at 20 mg once daily (1 tablet)

3rd Appearance

Consider permanent discontinuation

*The intensity of clinical adverse events graded by the Common Terminology Criteria for Adverse Events v4.0 (CTC-AE)
Dose modification advice for left ventricular dysfunction
Permanent discontinuation of Cotellic treatment should be considered if cardiac symptoms are attributed to Cotellic and do not improve after temporary interruption.
Table 2 Recommended dose modifications for Cotellic in patients with left ventricular ejection fraction (LVEF) decrease from baseline

Patient

LVEF value

Recommended Cotellic dose modification

LVEF value following treatment break

Recommended Cotellic daily dose

Asymptomatic

≥ 50%

(or 40-49% and < 10% absolute decrease from baseline)

Continue at current dose

N/A

N/A

< 40%

(or 40-49% and ≥ 10% absolute decrease from baseline)

Interrupt treatment for 2 weeks

< 10% absolute decrease from baseline

1st occurrence: 40 mg

2nd occurrence: 20 mg

3rd occurrence: permanent discontinuation

< 40%

(or ≥ 10% absolute decrease from baseline)

Permanent discontinuation

Symptomatic

N/A

Interrupt treatment for 4 weeks

Asymptomatic and < 10% absolute decrease from baseline

1st occurrence: 40 mg

2nd occurrence: 20 mg

3rd occurrence: permanent discontinuation

Asymptomatic and < 40%

(or ≥ 10% absolute decrease from baseline)

Permanent discontinuation

Symptomatic regardless of LVEF

Permanent discontinuation

N/A = Not Applicable
Vemurafenib treatment can be continued when Cotellic treatment is modified, if clinically indicated.
Dose modification advice for Cotellic when used with vemurafenib
Liver laboratory abnormalities
For Grade 1 and 2 liver laboratory abnormalities, Cotellic and vemurafenib should be continued at the prescribed dose.
Grade 3: Cotellic should be continued at the prescribed dose. The dose of vemurafenib may be reduced as clinically appropriate. Please refer to the vemurafenib SmPC.
Grade 4:
Cotellic treatment and vemurafenib treatment should be interrupted. If liver laboratory abnormalities improve to Grade ≤1 within 4 weeks, Cotellic should be restarted at a dose reduced by 20 mg and vemurafenib at a clinically appropriate dose, per its SmPC.
Cotellic treatment and vemurafenib treatment should be discontinued if liver laboratory abnormalities do not resolve to Grade ≤1 within 4 weeks or if Grade 4 liver laboratory abnormalities recur after initial improvement.
Creatine phosphokinase (CPK) elevations
Cotellic dosing does not need to be modified or interrupted to manage asymptomatic CPK elevations.
Photosensitivity
Grade ≤2 (tolerable) photosensitivity should be managed with supportive care.
Grade 2 (intolerable) or Grade ≥3 photosensitivity: Cotellic and vemurafenib should be interrupted until resolution to Grade ≤1. Treatment can be restarted with no change in Cotellic dose. Vemurafenib dosing should be reduced as clinically appropriate, please refer to its SmPC for further information.
Rash
Rash events may occur with either Cotellic or vemurafenib treatment. The dose of Cotellic and/or vemurafenib may be either temporarily interrupted and/or reduced as clinically indicated.
Additionally, for:
Grade ≤2 (tolerable) rash should be managed with supportive care. Cotellic dosing can be continued without modification.
Grade 2 (intolerable) or Grade ≥3 acneiform rash: General dose modification recommendations in Table 1 for Cotellic should be followed. Vemurafenib dosing can be continued when Cotellic treatment is modified (if clinically indicated).
Grade 2 (intolerable) or Grade ≥3 non-acneiform or maculopapular rash: Cotellic dosing can be continued without modification if clinically indicated. Vemurafenib dosing may be either temporarily interrupted and/or reduced, please refer to its SmPC for further information.
QT prolongation
If during treatment the QTc exceeds 500 msec, please refer to the vemurafenib SmPC (section 4.2) for dose modifications for vemurafenib. No dose modification of Cotellic is required when taken in combination with vemurafenib.
Special populations
Elderly patients
No dose adjustment is required in patients aged ≥65 years old.
Renal impairment
No dose adjustment is recommended in patients with mild or moderate renal impairment based on population pharmacokinetic analysis (see section 5.2). There are minimal data for Cotellic in patients with severe renal impairment, therefore an effect cannot be excluded. Cotellic should be used with caution in patients with severe renal impairment.
Hepatic impairment
The safety and efficacy of Cotellic has not been established in patients with hepatic impairment (see section 5.2). There are no pharmacokinetic data in patients with moderate or severe hepatic impairment. Cotellic should be used with caution in patients with moderate to severe hepatic impairment.
Non-Caucasian patients
The safety and efficacy of Cotellic in non-Caucasian patients have not been established.
Paediatric population
The safety and efficacy of Cotellic in children and adolescents below 18 years of age have not been established. No data are available.
Method of administration
Cotellic is for oral use. The tablets should be swallowed whole with water. They can be taken with or without food.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Before taking Cotellic in combination with vemurafenib, patients must have BRAF V600 mutation-positive tumour status confirmed by a validated test.
Cotellic in combination with vemurafenib in patients who have progressed on a BRAF inhibitor
There are limited data in patients taking the combination of Cotellic with vemurafenib who have progressed on a prior BRAF inhibitor. These data show that the efficacy of the combination will be lower in these patients (see section 5.1). Therefore other treatment options should be considered before treatment with the combination in this prior BRAF inhibitor treated population. The sequencing of treatments following progression on a BRAF inhibitor therapy has not been established.
Cotellic in combination with vemurafenib in patients with brain metastases
The safety and efficacy of the combination of Cotellic and vemurafenib have not been evaluated in patients with a BRAF V600 mutation-positive melanoma which has metastasised to the brain. The intracranial activity of cobimetinib is currently unknown (see sections 5.1 and 5.2).
Serous retinopathy
Serous retinopathy (fluid accumulation within the layers of the retina) has been observed in patients treated with MEK-inhibitors, including Cotellic (see section 4.8). The majority of events were reported as chorioretinopathy or retinal detachment.
Median time to initial onset of serous retinopathy events was 1 month (range 0-9 months). Most events observed in clinical trials were resolved, or improved to asymptomatic Grade 1, following dose interruption or reduction.
Patients should be assessed at each visit for symptoms of new or worsening visual disturbances. If symptoms of new or worsening visual disturbances are identified, an ophthalmologic examination is recommended. If serous retinopathy is diagnosed, Cotellic treatment should be withheld until visual symptoms improve to Grade ≤1. Serous retinopathy can be managed with treatment interruption, dose reduction or with treatment discontinuation (see Table 1 in section 4.2).
Left ventricular dysfunction
Decrease in LVEF from baseline has been reported in patients receiving Cotellic (see section 4.8). Median time to initial onset of events was 4 months (1-7 months).
LVEF should be evaluated before initiation of treatment to establish baseline values, then after the first month of treatment and at least every 3 months or as clinically indicated until treatment discontinuation. Decrease in LVEF from baseline can be managed using treatment interruption, dose reduction or with treatment discontinuation (see section 4.2).
All patients restarting treatment with a dose reduction of Cotellic should have LVEF measurements taken after approximately 2 weeks, 4 weeks, 10 weeks and 16 weeks, and then as clinically indicated.
Patients with a baseline LVEF either below institutional lower limit of normal (LLN) or below 50% have not been studied.
Liver laboratory abnormalities
Liver laboratory abnormalities can occur when Cotellic is used in combination with vemurafenib and with vemurafenib as a single agent (please refer to its SmPC).
Liver laboratory abnormalities, specifically increases in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Alkaline Phosphatase (ALP), have been observed in patients treated with Cotellic plus vemurafenib (see section 4.8).
Liver value abnormalities should be monitored by liver laboratory tests before initiation of combination treatment and monthly during treatment, or more frequently as clinically indicated (see section 4.2).
Grade 3 liver laboratory abnormalities should be managed with vemurafenib treatment interruption or dose reduction. Manage Grade 4 liver laboratory abnormalities with treatment interruption, dose reduction or with treatment discontinuation of both Cotellic and vemurafenib (see section 4.2).
Diarrhoea
Cases of Grade ≥3 and serious diarrhoea have been reported in patients treated with Cotellic. Diarrhoea should be managed with anti-diarrhoeal agents and supportive care. For Grade ≥3 diarrhoea that occurs despite supportive care, Cotellic and vemurafenib should be withheld until diarrhoea has improved to Grade ≤1. If Grade ≥3 diarrhoea recurs, the dose of Cotellic and vemurafenib should be reduced (see section 4.2).
Lactose intolerance
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, congenital lactase deficiency or glucose-galactose malabsorption should consult with their physician and discuss whether the benefits outweigh the risks on an individual basis.
Drug-drug interactions: CYP3A4 inhibitors
Concurrent use of strong CYP3A inhibitors during treatment with Cotellic should be avoided. Caution should be exercised if a moderate CYP3A4 inhibitor is co-administered with Cotellic. If concomitant use with a strong or moderate CYP3A inhibitor is unavoidable, patients should be carefully monitored for safety and dose modifications applied if clinically indicated (see Table 1 in section 4.2).
QT prolongation
If during treatment the QTc exceeds 500 msec, please refer to the vemurafenib SmPC sections 4.2 and 4.4.
4.5 Interaction with other medicinal products and other forms of interaction
Effects of other medicinal products on cobimetinib
CYP3A inhibitors
Cobimetinib is metabolized by CYP3A and cobimetinib AUC increased approximately 7 fold in the presence of a strong CYP3A inhibitor (itraconazole) in healthy subjects. The magnitude of interaction could potentially be lower in patients.
Strong CYP3A4 inhibitors (see section 4.4.): Avoid concurrent use of strong CYP3A inhibitors during treatment with cobimetinib. Strong CYP3A4 inhibitors include, but are not limited to ritonavir, cobicistat, telaprevir, lopinavir, itraconazole, voriconazole, clarithromycin, telithromycin, posaconazole, nefazodone and grapefruit juice. If concomitant use of a strong CYP3A inhibitor is unavoidable, patients should be carefully monitored for safety. For strong CYP3A inhibitors used short-term (7 days or less), consider interrupting cobimetinib therapy during the duration of inhibitor use.
Moderate CYP3A4 inhibitors (see section 4.4.): Caution should be exercised if cobimetinib is co-administered with moderate CYP3A inhibitors. Moderate CYP3A4 inhibitors include, but are not limited to, amiodarone, erythromycin, fluconazole, miconazole, diltiazem, verapamil, delavirdine, amprenavir, fosamprenavir, imatinib. When cobimetinib is co-administered with a moderate CYP3A inhibitor, patients should be carefully monitored for safety.
Mild CYP3A4 inhibitors: Cobimetinib can be co-administered with mild inhibitors of CYP3A without dose adjustment.
CYP3A inducers
Co-administration of cobimetinib with a strong CYP3A inducer was not assessed in a clinical study, however, a reduction in cobimetinib exposure is likely. Therefore, concomitant use of moderate and strong CYP3A inducers (e.g. carbamazepine, rifampicin, phenytoin, and St. John's Wort) should be avoided. Alternative agents with no or minimal CYP3A induction should be considered. Given that cobimetinib concentrations are likely to be significantly reduced when co-administered with moderate to strong CYP3A inducers, patient's efficacy may be compromised.
P-glycoprotein inhibitors
Cobimetinib is a substrate of P-glycoprotein (P-gp). Concomitant administration of P-gp inhibitors such as ciclosporin and verapamil may have the potential to increase plasma concentrations of cobimetinib.
Effects of cobimetinib on other medicinal products
CYP3A and CYP2D6 substrates
A clinical drug-drug interaction (DDI) study in cancer patients showed that plasma concentrations of midazolam (a sensitive CYP3A substrate) and dextromethorphan (a sensitive CYP2D6 substrate) were not altered in the presence of cobimetinib.
CYP1A2 substrates
In vitro, cobimetinib is a potential inducer of CYP1A2 and may therefore reduce the exposure of substrates of this enzyme e.g., theophylline. No clinical DDI studies have been conducted to assess the clinical relevance of this finding.
BCRP substrates
In vitro, cobimetinib is a moderate inhibitor of BCRP (Breast Cancer Resistance Protein). No clinical DDI studies have been conducted to assess this finding, and clinically relevant inhibition of intestinal BCRP cannot be ruled out.
Other anti-cancer agents
Vemurafenib
There is no evidence of any clinically significant drug-drug interaction between cobimetinib and vemurafenib in unresectable or metastatic melanoma patients and therefore no dose adjustments is recommended.
Effects of cobimetinib on drug transport systems
In vitro studies show that cobimetinib is not a substrate of the liver uptake transporters OATP1B1, OATP1B3 and OCT1, however, it weakly inhibits these transporters. The clinical relevance of these findings has not been investigated.
Padiatric population
Interaction studies have only been performed in adults.
4.6 Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential should be advised to use two effective contraceptive methods, such as a condom or other barrier method (with spermicide, if available) during treatment with Cotellic and for at least three months following treatment discontinuation.
Pregnancy
There are no data from the use of Cotellic in pregnant women. Studies in animals have shown embryolethality and foetal malformations of the great vessels and skull (see section 5.3). Cotellic should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus.
Breast-feeding
It is not known whether cobimetinib is excreted in human breast milk. A risk to the newborns/infants cannot be excluded. A decision should be made whether to discontinue breast-feeding or discontinue Cotellic therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility
There are no data in humans for cobimetinib. In animals, no fertility studies have been performed, but adverse effects were seen on female reproductive organs (see section 5.3). The clinical relevance of this is unknown.
4.7 Effects on ability to drive and use machines
Cotellic has minor influence on the ability to drive or use machines. Visual disturbances have been reported in some patients treated with cobimetinib during clinical trials (see sections 4.4 and 4.8). Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse effects that may affect their ability.
4.8 Undesirable effects
Summary of the safety profile
The safety of Cotellic in combination with vemurafenib has been evaluated in 254 patients with advanced BRAF V600 mutated melanoma in Study GO28141.The median time to onset of first Grade ≥3 adverse events was 0.5 months in the Cotellic plus vemurafenib arm vs 0.8 months in the placebo plus vemurafenib arm.
The safety of Cotellic in combination with vemurafenib has also been evaluated in 129 patients with advanced BRAF V600 mutated melanoma in Study NO25395. The safety profile of Study NO25395 was consistent with that observed in Study GO28141.
In Study GO28141, the most common adverse reactions (>20%) observed with a higher frequency in the Cotellic plus vemurafenib arm were diarrhoea, rash, nausea, pyrexia, photosensitivity reaction, increased alanine aminotransferase, increased aspartate aminotransferase, increased blood creatine phosphokinase, and vomiting. The most common adverse reactions (>20%) observed with a higher frequency in the placebo plus vemurafenib arm were arthralgia, alopecia, and hyperkeratosis. Fatigue was observed at similar frequencies in both arms.
Please refer to the vemurafenib SmPC for complete descriptions of all undesirable effects associated with vemurafenib treatment.
Tabulated list of adverse reactions
ADRs are based on results from a multi-centre, randomised, double-blind, placebo-controlled, Phase III Study (GO28141) that evaluated the safety and efficacy of Cotellic in combination with vemurafenib as compared to vemurafenib alone in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced (Stage IIIc) or metastatic melanoma (Stage IV).
ADRs which were reported in melanoma patients are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been used for the classification of frequency:
Very common ≥ 1/10
Common ≥ 1/100 to < 1/10
Uncommon ≥ 1/1,000 to < 1/100
Rare ≥ 1/10,000 to < 1/1,000
Very rare < 1/10,000
Table 3 lists adverse reactions considered associated with the use of Cotellic. Within each frequency grouping, ADRs are presented in order of decreasing severity and were reported according to NCI-CTCAE v 4.0 (common toxicity criteria) for assessment of toxicity in Study GO28141.
Table 3 Adverse drug reactions in patients treated with Cotellic in combination with vemurafenib in Study GO28141

System organ class

Very Common

Common

Neoplasms benign, malignant and unspecified (incl. cysts and polyps)

 

Basal cell carcinoma, Cutaneous squamous cell carcinoma**, Keratoacanthoma**

Blood and lymphatic system disorders

Anaemia

 

Metabolism and nutrition disorders

 

Dehydration, Hypophosphataemia, Hyponatremia, Hyperglycaemia

Eye disorders

Serous retinopathya

Blurred vision, Visual impairment

Vascular disorders

Hypertension, Haemorrhage*

 

Respiratory, thoracic and mediastinal disorders

 

Pneumonitis

Gastrointestinal disorders

Diarrhoea, Nausea, Vomiting

 

Skin and subcutaneous tissue disorders

Photosensitivityb, Rash, Rash maculo-papular, Dermatitis acneiform, Hyperkeratosis**

 

General disorders and administration site conditions

Pyrexia

Chills

Investigations

Blood CPK increased, ALT increased, AST increased, Gamma-Glutamyltransferase (GGT) increased, Blood ALP increased

Ejection fraction decreased, Blood bilirubin increased

* Please refer to the paragraph Haemorrhage in the"Description of selected adverse reactions" section
** Please refer to the paragraph Cutaneous squamous cell carcinoma, keratoacanthoma and hyperkeratosis in the “Description of selected adverse reactions” section.
a Includes both chorioretinopathy and retinal detachment events indicative of serous retinopathy (see section 4.4)
b Combined figure includes reports of photosensitivity reaction, sunburn, solar dermatitis, actinic elastosis
Description of selected adverse reactions
Haemorrhage
Bleeding events have been reported more frequently in the Cotellic plus vemurafenib arm than in the placebo plus vemurafenib arm (all types and Grades: 10% vs 6%). Higher frequencies in the Cotellic plus vemurafenib arm were observed for cerebral haemorrhage (1% vs 0%), gastrointestinal tract haemorrhage (3% vs 1%), reproductive system haemorrhage (2% vs 1%) and haematuria (2% vs 1%).
The majority of events were Grade 1 or 2 and non-serious (9% of patients in the Cotellic plus vemurafenib arm vs 5% patients in the placebo plus vemurafenib arm). Grade 3-5 events were experienced by 1% and 0.4% of patients, respectively. The median time to first onset was 2.8 months (range 0.0 to 12.7 months) in the Cotellic plus vemurafenib arm.
Photosensitivity
Photosensitivity has been observed with a higher frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm (41% vs 31%). The majority of events were Grades 1 or 2, with Grade ≥3 events occurring in 3% of patients in the Cotellic plus vemurafenib arm vs 0% in the placebo plus vemurafenib arm.
There were no apparent trends in the time of onset of Grade ≥3 events. Grade ≥3 photosensitivity events in the Cotellic plus vemurafenib arm were treated with primary topical medicinal products in conjunction with dose interruptions of both cobimetinib and vemurafenib (see section 4.2).
No evidence of phototoxicity was observed with Cotellic as a single agent.
Cutaneous squamous cell carcinoma, keratoacanthoma and hyperkeratosis
Cutaneous squamous cell carcinoma has been reported with a lower frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm (all Grade: 3% vs 11%). Keratoacanthoma has been reported with a lower frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm (all Grade: 1% vs 8%). Hyperkeratosis has been reported with a lower frequency in the Cotellic plus vemurafenib vs placebo plus vemurafenib arm (all Grade: 10% vs 29%).
Serous retinopathy
Cases of serous retinopathy have been reported in patients treated with Cotellic (see section 4.4.) For patients reporting new or worsening visual disturbances, an ophthalmologic examination is recommended. Serous retinopathy can be managed with treatment interruption, dose reduction or with treatment discontinuation (see Table 1 in section 4.2).
Left ventricular dysfunction
Decrease in LVEF from baseline has been reported in patients receiving Cotellic (see section 4.4). LVEF should be evaluated before initiation of treatment to establish baseline values, then after the first month of treatment and at least every 3 months or as clinically indicated until treatment discontinuation. Decrease in LVEF from baseline can be managed using treatment interruption, dose reduction or with treatment discontinuation (see section 4.2).
Laboratory abnormalities
Liver laboratory abnormalities
Liver laboratory abnormalities, specifically ALT, AST, and ALP have been observed in patients treated with Cotellic in combination with vemurafenib (see section 4.4).
Liver laboratory tests should be monitored before initiation of combination treatment and monthly during treatment, or more frequently if clinically indicated (see section 4.2).
Blood creatine phosphokinase increase
Asymptomatic increases in blood CPK levels were observed with a higher frequency in the Cotellic plus vemurafenib arm vs placebo plus vemurafenib arm in Study GO28141 (see section 4.2). One event of rhabdomyolysis was observed in each treatment arm of the Study with concurrent increases in blood CPK.
Table 4 provides the frequency of measured liver laboratory abnormalities and elevated creatine phosphokinase for all Grades and Grades 3-4.
Table 4 Liver and other laboratory tests observed in the Phase III Study GO28141

Changes in reported laboratory data

Cobimetinib plus Vemurafenib

(n = 254)

(%)

Placebo plus Vemurafenib

(n = 239)

(%)

 

All Grades

Grades 3-4

All Grades

Grades 3-4

Liver function test

Increased ALP

69

7

54

3

Increased ALT

66

10

53

6

Increased AST

69

7

42

2

Increased GGT

60

19

59

17

Increased blood bilirubin

33

2

43

1

Other laboratory abnormalities

Increased blood CPK

65

11

13

<1

Special populations
Elderly patients
In the Phase III study with Cotellic in combination with vemurafenib in patients with unresectable or metastatic melanoma (n=254), 189 patients (74%) were <65 years of age, and 44 patients (17%) were 65-74 years of age, 17 (7%) were 75-84 years of age, and 4 patients (2%) were aged ≥85 years The proportion of patients experiencing adverse events (AE) was similar in the patients aged <65 years and those aged ≥65 years. Patients ≥65 years were more likely to experience serious adverse events (SAEs) and experience AEs leading to discontinuation of cobimetinib than those <65 years.
Renal impairment
No pharmacokinetic trial in subjects with renal impairment has been conducted. Dose adjustment is not recommended for mild to moderate renal impairment based on the results of the population pharmacokinetic analysis. There are minimal data for Cotellic in patients with severe renal impairment. Cotellic should be used with caution in patients with severe renal impairment.
Hepatic impairment
No pharmacokinetic data in subjects with hepatic impairment are available.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below).
Ireland
HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie
Malta
ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
There is no experience with overdose in human clinical trials. In case of suspected overdose, cobimetinib should be withheld and supportive care instituted. There is no specific antidote for overdosage with cobimetinib.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38
Mechanism of action
Cobimetinib is a reversible, selective, allosteric, oral inhibitor that blocks the mitogen-activated protein kinase (MAPK) pathway by targeting the mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK 2 which results in inhibition of phosphorylation of the extracellular signal-regulated kinase (ERK) 1 and ERK 2. Therefore, cobimetinib blocks the cell proliferation induced by the MAPK pathway through inhibition of the MEK1/2 signalling node.
In the preclinical models, the combination of cobimetinib and vemurafenib showed that by simultaneously targeting mutated BRAF V600 proteins and MEK proteins in melanoma cells, the combination of the two products inhibits MAPK pathway reactivation through MEK1/2, resulting in a stronger inhibition of intracellular signalling and decreased tumour cell proliferation
Clinical efficacy and safety
There are no data on the safety or efficacy of Cotellic in combination with vemurafenib in patients with central nervous system metastasis or in patients with non-cutaneous malignant melanoma.
Study GO28141 (coBRIM)
Study GO28141 is a multi-centre, randomised, double-blind, placebo-controlled, Phase III study to evaluate the safety and efficacy of Cotellic in combination with vemurafenib as compared to vemurafenib plus placebo, in previously untreated patients with BRAF V600 mutation-positive unresectable locally advanced (Stage IIIc) or metastatic melanoma (Stage IV).
Only patients with ECOG performance status 0 and 1 were enrolled in Study GO28141. Patients with ECOG performance status 2 or higher were excluded from the study.
Following confirmation of a BRAF V600 mutation, using the cobas® 4800 BRAF V600 mutation test, 495 previously untreated patients with unresectable locally advanced or metastatic melanoma were randomised to receive either:
• Placebo once daily on Days 1-21 of each 28-day treatment cycle and 960 mg vemurafenib twice daily on Days 1-28, or
• Cotellic 60 mg once daily on Days 1-21 of each 28-day treatment cycle and 960 mg vemurafenib twice daily on Days 1-28
Progression-free survival (PFS) as assessed by the investigator (INV) was the primary endpoint. Secondary efficacy endpoints included overall survival (OS), objective response rate, duration of response (DoR) as assessed by INV and PFS as assessed by an independent review facility (IRF).
Key baseline characteristics included: 58% of patients were male, median age was 55 years (range 23 to 88 years), 60% had metastatic melanoma stage M1c and the proportion of patients with elevated LDH was 46.3% in the cobimetinib plus vemurafenib arm and 43.0% in the placebo plus vemurafenib arm.
In Study GO28141, there were 89 patients (18.1%) aged 65-74, 38 patients (7.7%) aged 75-84 and 5 patients (1.0%) aged 85 years and older.
Efficacy results are summarized in Table 5.
Table 5 Efficacy results from Study GO28141 (coBRIM) – Cut-off date 16 January 2015

Cotellic + vemurafenib

N=247

Placebo + vemurafenib

N=248

Primary Endpointa

Progression-Free Survival (PFS)

Median (months)

95 % CI

12.3

(9.5, 13.4)

7.2

(5.6, 7.5)

Hazard ratio (95% CI) b

0.58 (0.46; 0.72)

Key Secondary Endpointsa

Overall Survival (OS)

OS % at 12 months (95% CI)

74.9 (69.3, 80.5)

63.0 (56.8, 69.3)

Median (months)

95 % CI

NE (20.7, NE)

17.0 (15.0, NE)

Hazard ratio (95% CI)b

0.65 (0.49, 0.87)

Objective response rate (ORR)

172 (69.6%)

124 (50.0%)

95% CI for ORRc

(63.5%, 75.3%)

(43.6%, 56.4%)

Difference in ORR %

(95% CI) d

19.6 (11.0, 28.3)

Best Overall Response

Complete Response

39 (15.8%)

26 (10.5%)

Partial Response

133 (53.8%)

98 (39.5%)

Stable disease

44 (17.8%)

92 (37.1%)

Duration of Response (DoR)

Median DoR (months)

95% CI for median

13

(11.1, 16.6)

9.2

(7.5, 12.8)

NE = Not evaluable
a Assessed and confirmed by the investigator (INV) using RECIST v1.1
b Stratified analysis by geographic region and metastasis classification (disease stage)
c Using Clopper-Pearson method
d Using Hauck-Anderson method
The primary analysis for Study GO28141 was conducted with a data cut-off date of 09 May 2014. Significant improvement in the primary endpoint, investigator-assessed PFS, was observed in patients assigned to the Cotellic plus vemurafenib arm compared to the placebo plus vemurafenib arm (HR 0.51 (0.39; 0.68); p-value < 0.0001). The median estimate for investigator-assessed PFS was 9.9 months for the Cotellic plus vemurafenib arm vs. 6.2 months for the placebo plus vemurafenib arm. The median estimate for independent review of PFS was 11.3 months for the Cotellic plus vemurafenib arm vs. 6.0 months for the placebo plus vemurafenib arm (HR 0.60 (0.45; 0.79); p-value = 0.0003). The objective response rate (ORR) in the Cotellic plus vemurafenib arm was 67.6% vs 44.8% in the placebo plus vemurafenib arm. The difference in ORR was 22.9 % (p-value<0.0001).
Figure 1 Kaplan-Meier curves of progression-free survival (INV) – intent to treat population (cut-off date: 16 January 2015)


Figure 2 Forest plot for hazard ratios of progression-free survival subgroup analyses – intent to treat population (cut-off date: 16 January 2015)


Global health status / health-related quality of life by patient-report were measured using the EORTC Quality of Life Questionnaire – Core 30 (QLQ-C30). All functioning domains and most symptoms (appetite loss, constipation, insomnia, nausea and vomiting, dyspnoea, pain, fatigue) were similar between the two treatment arms and did not demonstrate a clinically meaningful change (≥ 10 point increase or decrease from baseline).
Study NO25395 (BRIM7)
The efficacy of Cotellic was evaluated in Phase Ib Study, NO25395, which was designed to assess the safety, tolerability, pharmacokinetics and efficacy of Cotellic when added to vemurafenib for the treatment of patients with BRAFV600 mutation-positive (as detected by the cobas® 4800 BRAF V600 Mutation Test), unresectable or metastatic melanoma.
This study treated 129 patients with Cotellic and vemurafenib: 63 were BRAF inhibitor (BRAFi) therapy naïve and 66 patients had previously progressed on prior vemurafenib therapy. Among the 63 BRAFi naïve patients, 20 patients had received prior systemic therapy for advanced melanoma with the majority (80%) being immunotherapy.
Results of the BRAFi naïve population from Study NO25395 were generally consistent with those from Study GO28141. The BRAFi-naïve patients (n꞊63) attained an 87% objective response rate, including a complete response in 10% of patients. The median duration of response was 12.5 months. The median PFS for BRAFi-naïve patients was 13.7 months, with median follow-up time of 12.7 months.
Among patients who had progressed on vemurafenib (n=66), the objective response rate was 15%. The median duration of response was 6.7 months. The median PFS for patients who had progressed on vemurafenib was 2.8 months.
In patients who were naive to BRAF inhibitor therapy, the overall survival at 1-year was 83% (95% CI 73, 93). In patients who had progressed on BRAF inhibitor therapy, the overall survival at 1-year was 32% (95% CI 19, 45).
Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Cotellic in one or more subsets of the paediatric population in malignant solid tumours (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties
Absorption
Following oral dosing of 60 mg in cancer patients, cobimetinib showed a moderate rate of absorption with a median Tmax of 2.4 hours. The mean steady-state Cmax and AUC0-24 were 273 ng/mL and 4340 ng.h/mL respectively. The mean accumulation ratio at steady state was approximately 2.4-fold.
Cobimetinib has linear pharmacokinetics in the dose range of ~3.5 mg to 100 mg.
The absolute bioavailability of cobimetinib was 45.9% (90% CI: 39.7%, 53.1%) in healthy subjects. A human mass balance study was conducted in healthy subjects, and showed that cobimetinib was extensively metabolised and eliminated in faeces. The fraction absorbed was ~88% indicating high absorption and first pass metabolism.
The pharmacokinetics of cobimetinib are not altered when administered in the fed state (high-fat meal) compared with the fasted state in healthy subjects. Since food does not alter the pharmacokinetics of cobimetinib, it can be administered with or without food.
Distribution
Cobimetinib is 94.8% bound to human plasma proteins in vitro. No preferential binding to human red blood cells was observed (blood to plasma ratio 0.93).
The volume of distribution was 1050 L in healthy subjects given an intravenous dose of 2 mg. The apparent volume of distribution was 806 L in cancer patients based on population pharmacokinetic analysis.
Cobimetinib is a substrate of P-gp in vitro. The transport across the blood brain barrier is unknown.
Biotransformation
Oxidation by CYP3A and glucuronidation by UGT2B7 appear to be the major pathways of cobimetinib metabolism. Cobimetinib is the predominant moiety in plasma. No oxidative metabolites greater than 10% of total circulating radioactivity or human specific metabolites were observed in plasma. Unchanged medicinal product in faeces and urine accounted for 6.6% and 1.6% of the administered dose, respectively, indicating that cobimetinib is primarily metabolised with minimal renal elimination. In vitro data indicate cobimetinib is not an inhibitor of OAT1, OAT3 or OCT2.
Elimination
Cobimetinib and its metabolites were characterised in a mass balance study in healthy subjects. On average, 94% of the dose was recovered within 17 days. Cobimetinib was extensively metabolised and eliminated in faeces.
Following intravenous administration of a 2 mg dose of cobimetinib, the mean plasma clearance (CL) was 10.7 L/hr. The mean apparent CL following oral dosing of 60 mg in cancer patients was 13.8 L/hr.
The mean elimination half-life following oral dosing of cobimetinib was 43.6 hours (range: 23.1 to 69.6 hours). Therefore, it may take up to 2 weeks following treatment cessation for cobimetinib to be completely removed from systemic circulation.
Special populations
Based on a population pharmacokinetic analysis, gender, race, ethnicity, baseline ECOG, mild and moderate renal impairment did not affect the pharmacokinetic of cobimetinib. Baseline age and baseline body weight were identified as statistically significant covariates on cobimetinib clearance and volume of distribution respectively. However, sensitivity analysis suggests neither of these covariates had clinically significant impact on steady state exposure.
Gender
Gender does not have an effect on the exposure of cobimetinib, based on a population pharmacokinetic analysis including 210 women and 277 men.
Elderly
Age does not have an effect on the exposure of cobimetinib, based on a population pharmacokinetic analysis including 133 patients ≥ 65 years of age.
Renal impairment
Based on preclinical data and the human mass balance study, cobimetinib is mainly metabolised, with minimal renal elimination. No formal pharmacokinetic study has been conducted in patients with renal impairment.
A population pharmacokinetic analysis using data from 151 patients with mild renal impairment (creatinine clearance (CRCL) 60 to less than 90 mL/min), 48 patients with moderate renal impairment (CRCL 30 to less than 60 mL/min), and 286 patients with normal renal function (CRCL greater than or equal to 90 mL/min), showed that CRCL had no meaningful influence on exposure of cobimetinib.
Mild to moderate renal impairment does not influence cobimetinib exposure based on the population pharmacokinetic analysis. There are minimal data for Cotellic in patients with severe renal impairment.
Hepatic impairment
No pharmacokinetic data in subjects with hepatic impairment are available.
Paediatric population
No studies have been conducted to investigate the pharmacokinetics of cobimetinib in paediatric patients.
5.3 Preclinical safety data
Carcinogenicity studies have not been conducted with cobimetinib. Standard genotoxicity studies with cobimetinib were negative.
No dedicated fertility studies in animals have been performed with cobimetinib. In the repeat-dose toxicology studies, degenerative changes were observed in reproductive tissues including increased apoptosis/necrosis of corpora lutea and seminal vesicle, epididymal and vaginal epithelial cells in rats, and epididymal epithelial cells in dogs. The clinical relevance of this is unknown.
When administered to pregnant rats, cobimetinib caused embryolethality and foetal malformations of the great vessels and skull at systemic exposures similar to human exposure at recommended dose.
Cardiovascular safety of cobimetinib in combination with vemurafenib has not been evaluated in vivo. In vitro, cobimetinib produced moderate hERG ion channel inhibition (IC50꞊ 0.5 µM [266 ng/mL]), which is approximately 18 fold higher than peak plasma concentrations (Cmax) at the 60 mg to be marketed dose (unbound Cmax꞊14 ng/mL [0.03 µM]).
Toxicity studies in rats and dogs identified generally reversible degenerative changes in the bone marrow, gastrointestinal tract, skin, thymus, adrenal gland, liver, spleen, lymph node, kidney, heart, ovary, and vagina at plasma exposures below clinical efficacious levels. Dose limiting toxicities included skin ulcerations, surface exudates, and acanthosis in the rat and chronic active inflammation and degeneration of the oesophagus associated with varying degrees of gastroenteropathy in dogs.
In a repeat dose toxicity study in juvenile rats, cobimetinib systemic exposures were 2 to11 fold higher on post natal day 10 than on post natal day 38 when exposures were similar to those in adult rats. In juvenile rats, cobimetinib administration resulted in similar changes as seen in the pivotal toxicity studies in adults, including reversible degenerative changes in the thymus and liver, decreased spleen and thyroid/parathyroid weights, increased phosphorus, bilirubin and red blood cell mass and decreased triglycerides. Mortality occurred in juvenile animals at a dose (3 mg/kg) which did not lead to mortalities in adult animals.
6. Pharmaceutical particulars
6.1 List of excipients
Tablet core
Lactose monohydrate
Microcrystalline cellulose (E460)
Croscarmellose sodium (E468)
Magnesium stearate (E470b)
Film coating
Polyvinyl alcohol
Titanium dioxide (E171)
Macrogol 3350
Talc (E553b)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
2 years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Transparent PVC/PVDC blisters containing 21 tablets. Each pack contains 63 tablets.
6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom
8. Marketing authorisation number(s)
EU/1/15/1048/001
9. Date of first authorisation/renewal of the authorisation
20 November 2015
10. Date of revision of the text
15 December 2015
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
---------------------------------------
产地国家:德国
原产地英文商品名:
Cotellic film-coated tablets 20mg/tablets  63tablets/box
原产地英文药品名:
COBIMETINIB FUMARATE
中文参考商品译名:
Cotellic片 20毫克/片 63片/瓶
中文参考药品译名:
COBIMETINIB FUMARATE
生产厂家中文参考译名:
罗氏
生产厂家英文名:
Roche

---------------------------------------
产地国家:美国 
原产地英文商品名:
Cotellic 20mg/tablets  63tablets/bottle
原产地英文药品名:
COBIMETINIB FUMARATE
中文参考商品译名:
Cotellic片 20毫克/片 63片/瓶
中文参考药品译名:
COBIMETINIB FUMARATE
生产厂家中文参考译名:
Genentech
生产厂家英文名:
Genentech

责任编辑:admin


相关文章
白血病新药Blincyto已获欧盟批准用于急性淋巴细胞白血病
突破性抗癌药venetoclax获欧盟受理上市许可
欧盟批准Cotellic罗氏组合疗法治疗晚期黑色素瘤
TAGRISSO filmcoated tablets(塔格瑞斯薄膜片)
Venetoclax(Venclexta)Tablets
VENCLEXTA(venetoclax)片为新类治疗白血病
Venetoclax Tablets(Venclexta/ABT-199)
Venclexta(venetoclax Tablets)
Tagrisso Tablets(Osimertinib Mesilate)
DEFITELIO(defibrotide sodium injection)
Defitelio(defibrotide-sodium)临床对造血干细胞移植治疗
 

最新文章

更多

· TREANDA(bendamustine h...
· LARTRUVO(olaratumab)注射液
· Cabometyx(cabozantini...
· 乐伐替尼硬胶囊|Kisplyx...
· Casodex(Bicalutamide F...
· 卡莫司汀用于注射|BiCNU...
· Lonsurf(Trifluridine/...
· Yondelis(ET-743,Trabec...
· KYTRIL Tablet(盐酸格拉...
· AKYNZEO(netupitant/pal...

推荐文章

更多

· TREANDA(bendamustine h...
· LARTRUVO(olaratumab)注射液
· Cabometyx(cabozantini...
· 乐伐替尼硬胶囊|Kisplyx...
· Casodex(Bicalutamide F...
· 卡莫司汀用于注射|BiCNU...
· Lonsurf(Trifluridine/...
· Yondelis(ET-743,Trabec...
· KYTRIL Tablet(盐酸格拉...
· AKYNZEO(netupitant/pal...

热点文章

更多

· LARTRUVO(olaratumab)注射液
· TREANDA(bendamustine h...